Liquidity Agreement Monthly Update and Total Voting Rights

Liquidity Agreement -1 December Paris, France and Cambridge, UK – 1 December 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by

Visit Page

FOR THE SECOND YEAR RUNNING NOVACYT WINS TECHNOLOGY FAST 50 AWARD

Novacyt Technology Fast 50 Award 2017 ENG Paris, France and Cambridge, UK – 7 November 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has won, for the second consecutive year, the Ile-de-France award of the Deloitte Technology Fast 50 French programme, an initiative that rewards fast

Visit Page

SETTLEMENT AND REDEMPTION OF ALL OUTSTANDING YORKVILLE CONVERTIBLE BONDS

Settlement and redemption of convertible bonds with Yorkville ENG Removes potentially dilutive instrument Strengthened balance sheet supports future growth

Visit Page

ADMISSION AND FIRST DAY OF DEALINGS ON AIM

Novacyt admission and first day of dealings AIM ENG Paris, France and Cambridge, UK – 1st November 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce the admission of the Company’s Shares (the “Enlarged Share Capital”) to trading on AIM, a market operated by the London

Visit Page

PROPOSED ADMISSION TO TRADING ON AIM AND SUCCESSFUL CONDITIONAL CAPITAL RAISE OF €9.7 MILLION

Novacyt proposed admission to AIM ENG Paris, France and Cambridge, UK – 18th October 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces that it has raised a total of €9.7 million (before expenses) through a conditional placing (the “Placing”) of 7,051,590 new shares (the “Placing Shares”), raising €4.7 million, and

Visit Page

NOVACYT STRENGTHENS PRIMERDESIGN BUSINESS WITH NEW SENIOR HIRE

Novacyt Senior Hire for PrimerDesign PR Eng Paul Eros joins as Commercial Director, completing investment in the Group’s senior leadership team  

Visit Page

Novacyt announces further progress in China

Novacyt announces largest order in China PR ENG Largest order in China for Primerdesign q16 instruments NOVAprep® demand growing  

Visit Page

NOVACYT HALF YEAR 2017 RESULTS Consolidated sales growth +53% CER Group continues positive outlook for 2017

Novacyt half year 2017 results ENG Paris, France and Cambridge, UK – 16th August 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces unaudited reviewed financial results for the six months ended 30 June 2017.

Visit Page

NOVACYT REVENUES HALF YEAR 2017 Consolidated sales growth +53% CER Group continues positive outlook for 2017

Novacyt revenues half year 2017 ENGLISH Paris, France and Cambridge, UK – 20th July 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces its unaudited revenues for the six months ended 30 June 2017 (the “Period”).

Visit Page

NOVACYT SUCCESSFULLY COMPLETES €3.0M FUNDRAISING

Novacyt Financing PR ENG (20-06-17) FINAL Momentum towards profitability continues through H1 2017 Investing to support increased sales demand across business

Visit Page